PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2022
CASE
AUTH/3630/4/22 Daiichi-Sankyo UK

Daiichi Sankyo: Lixiana HCP mobile site hid PI and AE reporting behind collapsible menu (AUTH/3630/4/22)

PMCPA found Daiichi Sankyo’s Lixiana HCP mobile homepage made prescribing info and AE reporting insufficiently prominent by placing them behind an expandable…

2022
CASE
AUTH/3639/4/22 Roche Products

Roche Products Ltd – Polivy dosing webpage omitted key administration instructions (AUTH/3639/4/22)

Polivy dosing webpage gave the impression it contained all key administration info, but omitted SPC instructions on a dedicated infusion line/filter and…

2022
CASE
AUTH/3638/4/22 Novartis Pharmaceuticals UK

Novartis breached ABPI Code over β€˜Think Symptom-free’ claim for Xolair on HCP website (AUTH/3638/4/22)

Novartis’ HCP website claim β€œTHINK Symptom-free” for Xolair in CSU was ruled misleading and unsubstantiated (Clauses 6.1, 6.2, 5.1). Other claims (β€œUNLOCK…

2022
CASE
AUTH/3706/11/22 CSL Vifor ⭐ Case of the Week

CSL Vifor: NHS IV iron service alleged to be disguised promotion for Ferinject (AUTH/3706/11/22) – No breach

Ex-employee alleged CSL Vifor’s non-promotional NHS service was targeted to Ferinject-using hospitals and amounted to disguised promotion/inducement. Panel found allegations not evidenced…

2021
CASE
Astellas Pharma

Astellas voluntary admission: transfers of value not disclosed to HCOs and patient organisations (2019–2021)

Astellas self-reported undisclosed transfers of value to two healthcare organisations and five patient organisations (2019–2021). PMCPA found multiple disclosure breaches and a…

2022
CASE
AUTH/3700/10/22 Ethypharm

Ethypharm naloxone poster on telephone booth ruled to be public advertising of a POM (AUTH/3700/10/22)

A naloxone awareness poster on a telephone booth linked to a website showing branded naloxone products. PMCPA ruled it advertised a POM…

2021
CASE
Janssen

Janssen: PAH symposium video ruled misleading (relative risk without absolute risk; mislabelled ARR; TRITON context missing)

PMCPA found Janssen breached Clauses 5.1 and 6.1 (x3) over a PAH symposium video: relative risk shown without absolute risk, ARR mislabelled,…

2023
CASE
AUTH/3757/3/23 Otsuka

Otsuka criticised for lack of transparency in PMCPA submission about earlier case (AUTH/3757/3/23)

Ex-employee alleged Otsuka withheld relevant facts and used unsigned witness statements in a 2015 PMCPA case response. Panel found breaches of Clauses…

2022
CASE
AUTH/3717/12/22 Novo Nordisk ⭐ Case of the Week

AUTH/3717/12/22: Public complaint about weight-loss media coverage – Novo Nordisk (Sunday Times interview led to breaches)

Five weight-loss media articles were complained about. Novo Nordisk was not responsible for four. One Sunday Times interview quote was ruled promotional…

2023
CASE
AUTH/3772/6/23 Daiichi-Sankyo UK

Daiichi Sankyo: Nustendi email found misleading due to implied comparator (AUTH/3772/6/23)

A third‑party promotional email for Nustendi quoted a β€œ38% LDL‑C reduction (placebo‑corrected)”. The PMCPA ruled the layout implied this was vs ezetimibe…

2023
CASE
AUTH/3785/6/23 GlaxoSmithKline

GSK breached ABPI Code over β€œTrevor trusts Trelegy” website claim (AUTH/3785/6/23)

PMCPA ruled GSK’s β€œTrevor trusts Trelegy” claim on an HCP website was ambiguous, misleading and unsubstantiated (Clauses 6.1, 6.2, 5.1). No breach…

2023
CASE
AUTH/3797/7/23 Besins Healthcare

AUTH/3797/7/23: Complainant v Besins Healthcare β€” alleged disguised promotion on Besins Hormone Academy website (No breach)

Complaint alleged Besins Hormone Academy webpages were disguised promotion. Panel found it was clearly a Besins HCP site with PI link and…

2021
CASE
CSL Vifor

CSL Vifor: Uncertified global invite to UK HCP for overseas CKD-aP meeting (difelikefalin) breached certification and mandatory info rules

CSL Vifor voluntarily admitted breaches after a global team sent a UK HCP an uncertified email invite/flyer for an overseas CKD-aP meeting…

2023
CASE
AUTH/3837/10/23 AstraZeneca ⭐ Case of the Week

AstraZeneca found in breach over HCP tweet lacking disclosure of company involvement in Speak Up for COPD campaign (AUTH/3837/10/23)

PMCPA ruled AstraZeneca breached Clause 5.5 after a contracted HCP tweeted #speakupforCOPD without declaring their association. Website disclosure was deemed sufficiently prominent;…

2023
CASE
AUTH/3835/10/23 Moderna

Moderna employee’s policy articles and X activity: lack of transparency, one public POM advert and compliance framework failings (AUTH/3835/10/23)

PMCPA found Moderna responsible for a senior employee’s policy articles and X reposts. Missing disclosure breached Clause 5.5 and high standards (5.1).…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training